Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Subscribe To Our Newsletter & Stay Updated